|
Robert C Bourge describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo A Multi-Institutional Study in patients with PAH RAPID TRANSTION FROM INHALED ILOPROST TO INHAED TREPROSTINIL IN PAH We tested the feasibility and safely of the rapid transition from inhaled iloprost (6-9 times per day) to inhaled treprostinil (4 times per day) and therapy for pulmonary arterial hypertension. In 69 of 73 patients, treated at 9 institutions, the switch was well tolerated and demonstrated improved patient satisfaction, and, over 12 weeks, an improvement in exercise capacity, probably due to improved compliance. The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación The University of Alabama at Birmingham, Birmingham, Alabama, United States  Authors' Report Crónica del Autor Bibliographic references Referencias bibliográficas 1. Ventavis (iloprost) inhalation solution. City, State; Actelion Pharmaceuticals Ltd. 2013. 2. Tyvaso (treprostinil) inhalation solution. Research Triangle Park, NC; United Therapeutics Corporation, 2014. 3. Bourge RC, Tapson VF, Safdar Z, et al. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovascular Ther 31:38-44, 2013. Other articles written by the author Robert C Bourge Otros artículos de Robert C Bourge Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koener SK, Langleben D, Keller CA, Uretsky BF, Murali S, Clayton LM, Jobsis MM, Crow JW, and the Primary Pulmonary Hypertension Study Group. Continuous intravenous prostacyclin versus conventional therapy in primary pulmonary hypertension: Results of a 12-week randomized trial in 81 patients. New England J Med 334:296-301, 1996. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jobsis MM, Blackburn SD, Crow JW, Long W, and the Primary Pulmonary Hypertension Study Group. Effects of chronic infusion of epoprostenol (prostacyclin) on echocardiographic measures of right heart structure and function in primary pulmonary hypertension. Circulation 95:1479-1486, 1997. Castro PF, Bourge RC, McGiffin DC, Benza RL, Fan P, Pinkard N, McGoon MD. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium. Chest 114:334-336, 1998. Badesch DB, Tapson VF, McGoon MD, Brundage, BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott G, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA, Gaine SP, Horn E, Decker JC, Knobil K. Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. Ann Intern Med 132:425-434, 2000. 5. Simonneau G, Barst RJ, Galie N, Jaeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ for the UT-15 Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804, 2002. 6. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S, on behalf of the Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. J Cardiovascular Pharmacology 41:293-299, 2003. 7. Benza RL, Rayburn BK, Tallaj JA, Coffey CS, Pinderski LJ, Pamoukian SV, Bourge RC. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 129:1009-1015, 2006. 8. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJc Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 152:521-526, 2006. 9. Frantz RP, Benza RL, Kjellstrom B, Bourge RC, Barst RJ, Bennett TD, McGoon MD. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 27:780-88, 2008. 10. Castro PF, Greig D, Verdejo HE, Godoy I, Córdova S, Ferrada MP, Bourge RC. Intrapulmonary shunting associated with sildenafil treatment in a patient with idiopathic pulmonary arterial hypertension. Thorax [Epub ahead of print]; 66(12):1097-1098, 2011. SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo Rapid Transition From Inhaled Iloprost to Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension Author / Autor Robert C Bourge1, Chad Messick2 2 Pharm D, United Therapeutics Corp, Global Medical Affairs Access to the original source Cardiovascular Therapeutics siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
||||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
